NFKB1 and opsoclonus-myoclonus syndrome: Notably, pre- and post-treatment of inhibitors of NF-κB signaling pathway [BAY 11–7082 (BAY) or TPCA-1] significantly increased the intracellular survival of Mabc in OMS-treated BMDMs.